Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 5.040 UNCHANGED Streaming Delayed Price Updated: 4:15 PM EDT, Apr 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 5.040 Bid (Size) 4.730 (5) Ask (Size) 5.040 (1) Prev. Close 5.040 Today's Range 5.040 - 5.040 52wk Range 1.630 - 8.830 Shares Outstanding 98,384,456 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Where Fate Therapeutics Stands With Analysts April 11, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session April 10, 2024 Via Benzinga Performance YTD +36.59% +36.59% 1 Month -28.00% -28.00% 3 Month +16.40% +16.40% 6 Month +145.85% +145.85% 1 Year -20.75% -20.75% More News Read More Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Evaluating Fate Therapeutics: Insights From 5 Financial Analysts March 19, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics February 27, 2024 Via Benzinga Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement March 19, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) March 05, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present at Upcoming March Investor Conferences March 01, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Recap: Fate Therapeutics Q4 Earnings February 26, 2024 Via Benzinga A Preview Of Fate Therapeutics's Earnings February 23, 2024 Via Benzinga Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday February 27, 2024 Via Benzinga Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates February 26, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Analyst Ratings for Fate Therapeutics November 09, 2023 Via Benzinga Recap: Fate Therapeutics Q3 Earnings November 08, 2023 Via Benzinga Earnings Scheduled For February 26, 2024 February 26, 2024 Via Benzinga Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock January 29, 2024 Via InvestorPlace Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors January 08, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session January 03, 2024 Via Benzinga Topics Stocks Exposures US Equities Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 13, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's After-Market Session December 12, 2023 Via Benzinga Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates November 08, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm November 03, 2023 From Bragar Eagel & Squire Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.